source
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.BioPharma Dive · 1h ago↗ source
- FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live LongerFDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.